Explore
Validate
LearnMA1-26837
antibody from Invitrogen Antibodies
Targeting: DMD
BMD, DXS142, DXS164, DXS206, DXS230, DXS239, DXS268, DXS269, DXS270, DXS272, MRX85
Western blot
ImmunohistochemistryAntibody data
- Antibody Data
- Antigen structure
- References [2]
- Comments [0]
- Validations
- Immunohistochemistry [1]
- Other assay [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MA1-26837 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- Anti-Dystrophin Monoclonal Antibody (MANDRA1)
- Antibody type
- Monoclonal
- Antigen
- Other
- Description
- Recommended positive controls: human muscle.
- Reactivity
- Human, Mouse, Rat
- Host
- Mouse
- Isotype
- IgG
- Antibody clone number
- MANDRA1
- Vial size
- 100 µL
- Concentration
- 6.6 mg/mL
- Storage
- Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
Submitted references KLF2 in Myeloid Lineage Cells Regulates the Innate Immune Response during Skeletal Muscle Injury and Regeneration.
Dilated cardiomyopathy-mediated heart failure induces a unique skeletal muscle myopathy with inflammation.
Manoharan P, Song T, Radzyukevich TL, Sadayappan S, Lingrel JB, Heiny JA
iScience 2019 Jul 26;17:334-346
iScience 2019 Jul 26;17:334-346
Dilated cardiomyopathy-mediated heart failure induces a unique skeletal muscle myopathy with inflammation.
Song T, Manoharan P, Millay DP, Koch SE, Rubinstein J, Heiny JA, Sadayappan S
Skeletal muscle 2019 Jan 24;9(1):4
Skeletal muscle 2019 Jan 24;9(1):4
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemistry analysis of Dystrophin was performed in human tongue tissue using Dystrophin Monoclonal Antibody (MANDRA1) (Product # MA1-26837) at a dilution of 1:100.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Fig. 6 Impaired functional recovery and muscle regenerative capacity after injury. a Representative Po graph during eccentric muscle contraction (ECC). b Po recovery at 3, 7, and 14 days after ECC injury. c Numbers of CN (top) and eMHC+ fibers (bottom) were counted on injured LG at 7 (left) and 14 days (right) post-injury and compared between t/t and WT groups. d Cross-sectioned images of injured LG stained by H&E (top) and immunostained with antibodies (eMHC; green, dystrophin; red, and DAPI; blue, bottom). Scale bar:50 mum. Arrowhead indicates necrotic fiber. Number of muscle samples = 3 in each group. ** P < 0.01 vs. t/t; * P < 0.05 vs. day 3
